Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020.

ABSTRACT:

Importance

Among older women (aged ≥50 years) with ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer, research has shown racial and ethnic disparities in access to ERBB2-targeted therapies, with Black women receiving treatment at lower rates than their White counterparts.

Objective

To examine racial and ethnic disparities in receipt of ERBB2-targeted therapies and changes in receipt over time.

Design, setting, and participants

This retrospective cohort study used Surveillance, Epidemiology, and End Results-Medicare linked data from January 1, 2010, to December 31, 2020. Beneficiaries who were diagnosed with ERBB2-positive breast cancer between 2010 and 2019, were aged 66 years or older at diagnosis, were continuously enrolled in Medicare Parts A and B in the 12

SUBMITTER: Krishnamurthy S 

PROVIDER: S-EPMC12046428 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature